R&D channel feed

FDA asks for more da­ta on Dupix­ent in COPD in move that could de­lay a de­ci­sion

Last year
Pharma
FDA+

As it cuts costs and pipeline, Bris­tol My­ers hands back a can­cer drug to Schrödinger

Last year

FDA de­ci­sion on Sarep­ta’s Duchenne gene ther­a­py could come ear­li­er than ex­pect­ed

Last year
Cell/Gene Tx
FDA+

Lil­ly scraps tri­als of Verzenio, Jar­diance and a gene ther­a­py from Pre­vail

Last year
Pharma

No­var­tis hands Pep­tiDream $180M up­front to ex­tend ra­dio­phar­ma dis­cov­ery pact

Last year
Deals

Mer­ck touts up­dat­ed 21-va­lent pneu­mo­coc­cal da­ta weeks ahead of FDA de­ci­sion: Cor­rect­ed

Last year

Prime Med­i­cine re­ceives FDA clear­ance to run first prime edit­ing clin­i­cal tri­al

Last year
Cell/Gene Tx
FDA+

As­traZeneca, Dai­ichi Sankyo’s En­her­tu claims an­oth­er Phase 3 vic­to­ry in HER2-low breast can­cer

Last year

Lead drug from J&J and Ad­dex's 20-year col­lab­o­ra­tion flunks Phase 2 in epilep­sy

Last year

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Last year
AI

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

Last year
Pharma

An­oth­er quar­ter, an­oth­er Keytru­da win for Mer­ck

Last year
Pharma

Astel­las cuts a bis­pe­cif­ic in can­cer and a mi­to­chon­dria-fo­cused as­set from Mi­to­bridge deal

Last year
Pharma

Mer­ck KGaA to ex­pand Ger­man head­quar­ters with €300M+ re­search cen­ter 

Last year
Manufacturing

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Last year
China

Astel­las' Friedre­ich’s atax­ia gene ther­a­py cleared for clin­i­cal study af­ter ear­li­er ver­sion stum­bled

Last year
Cell/Gene Tx

FDA's bi­o­log­ics chief Pe­ter Marks pre­views ac­cel­er­at­ed ap­proval guid­ance

Last year
Pharma
FDA+

Cure­Vac to cut costs, starts GSK-part­nered bird flu vac­cine tri­al

Last year
Pharma

To bring bold promis­es to fruition, Mod­er­na col­lab­o­rates with Ope­nAI on Chat­G­PT tech

Last year
Deals

Dutch biotech at­tracts J&J sup­port for can­cer pipeline in $21M Se­ries A

Last year
Financing

No­var­tis’ sim­pli­fied strat­e­gy takes shape as the com­pa­ny seeks for­mer Bris­tol My­ers CEO as chair

Last year
Pharma

Neu­ro­crine’s de­pres­sion drug pass­es Phase 2 tri­al

Last year

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

Last year
Startups
Deals

Sanofi’s BTK in­hibitor from Prin­cip­ia deal suc­ceeds in Phase 3 im­mune throm­bo­cy­tope­nia tri­al

Last year
First page Previous page 44454647484950 Next page Last page
A service from the Financial Times